MedMira Headquarters Visited by China's State Food and Drug Administration

MedMira Headquarters Visited by China's State Food and Drug
Administration
Only Canadian Company to Receive State Agency Visit 


HALIFAX, April 21  /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX
Venture: MIR, NASDAQ: MMIRF) the global market leader in rapid flow-through
diagnostic technology, announced today that two directors from China's State
Food and Drug Administration (SFDA) recently visited MedMira's corporate
offices and manufacturing facilities in Halifax, Nova Scotia. The directors
were part of an eight-member delegation from the SFDA, invited by the United
States and Canadian regulatory bodies.

The SFDA is the state authority in China governing all drug and medical devices
manufactured by both domestic and foreign companies. The Biological Division of
the SFDA is responsible for review and approval of HIV testing devices, such as
MedMira's currently approved MiraWell(TM) Rapid HIV Test and the new rapid
fingerstick whole blood test, which is undergoing clinical trials in China.
MedMira is the only Canadian company currently licensed to import rapid HIV
tests into China.

"We were pleased to visit MedMira and observe their high-quality manufacturing
facilities," said Dr. Yin Hongjhang, Director of the Biological Division of the
SFDA during his speech at a dinner reception. "We are thrilled to have gained
the opportunity to view, first-hand, the upcoming products for which MedMira
plans to seek our approval." Dr. Chang Yongheng, Director of the Product
Registration Division of the SFDA, also presented an updated SFDA approval
algorithm for new medical devices at the reception.

"We greatly welcomed this visit from the SFDA delegates in our Halifax
facilities, and are extremely thankful to representatives from our federal and
provincial governments and business community who joined us to greet our
guests," said Stephen Sham, Chairman and CEO of MedMira. "As we continue to
increase our product portfolio in the China market, we are delighted to see the
interest from these two directors in our newest innovations."

MedMira's MiraWell(TM) Rapid HIV test is currently used by public health
organizations in China's Jilin province, a result of the first provincial
government tender to be awarded to a Canadian company. It was recently ranked
the number one rapid HIV test in overall performance in a 2004 China National
Center for Disease Control (CDC) report.

About MedMira

MedMira is the leading global manufacturer and marketer of in vitro
flow-through rapid diagnostic tests for the clinical laboratory market.
MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the
detection of human antibodies in human serum, plasma or whole blood for
diseases such as HIV. The United States FDA and the SFDA in the People's
Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid
HIV Tests, respectively.

MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in
clinical laboratories and hospitals where professional counseling and patient
treatment are immediately available.

The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter (OTC) in
pharmacies throughout the Hong Kong and Macao Special Administrative Regions,
in the People's Republic of China.

MedMira markets its rapid tests worldwide in such countries as the United
States, Canada, South Africa and China. Its corporate offices and manufacturing
facilities are located in Halifax, Nova Scotia, Canada with a representative
office in Beijing, China.

This news release contains forward-looking statements, which involve risk and
uncertainties and reflect the company's current expectation regarding future
events. Actual events could materially differ from those projected herein and
depend on a number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies, uncertainties
related to the regulatory approval process, establishment of corporate
alliances and other risks detailed from time to time in the company quarterly
filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility
for the adequacy or accuracy of this statement.

For more information visit MedMira's website at http://www.medmira.com/. 

DATASOURCE: MedMira Inc.



CONTACT: Dr. James Smith, Investor Relations, Tel: [phone],

E-mail: 

Copyright